Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) has entered into a Memorandum of Understanding (MOU) with Celdara Medical, aiming to identify and advance innovative new therapeutics in areas of high unmet medical need. This collaboration will facilitate the exchange of non-competitive information from academic funding proposals, allowing both organizations to expand opportunities for financial support in the development of early-stage therapeutics.
TRxA, a global drug discovery and development accelerator launched in June 2022, focuses on supporting academic scientists in taking cutting-edge small molecule therapeutics from the laboratory to patients. By leveraging C-Path’s expertise in translational and regulatory science, TRxA provides funding and drug development guidance to its grantees, assisting them in developing comprehensive data packages for potential drug candidates. This comprehensive approach increases the likelihood of attracting investments from biotechnology and pharmaceutical companies for further clinical trials.
Celdara Medical, founded in 2008, has established a robust pipeline of potential therapeutics for diseases with unmet needs. Many of these opportunities align with TRxA’s strategic objectives, along with a mutual emphasis on patient need and experience.
Dr. Jake Reder, Co-founder and CEO of Celdara Medical, expressed his enthusiasm for the collaboration, stating, At Celdara Medical, we advance therapies with the potential to make a meaningful difference in the lives of patients. This collaboration with TRxA will improve the efficiency of both organizations, expanding complementary access to our respective innovation pipelines.
Dr. Julie Coleman, Director at Celdara Medical, emphasized the shared commitment to breaking down barriers in drug development, stating, This MOU reflects our shared commitment to breaking down barriers in drug development. By sharing resources and expertise with TRxA, we are poised to make significant strides in identifying important inventions and advancing treatments for patients with urgent medical needs.
Dr. Maaike Everts, Executive Director of TRxA, also highlighted the significance of collaboration, noting, Drug discovery and development is a team sport; many types of expertise, funding models, and organizations need to come together to mature an idea into a therapy available to patients. I am very excited to work together with Celdara Medical to find the best environment and expertise needed to ensure our best and brightest ideas get nurtured into new medicines.
The MOU between C-Path and Celdara Medical underscores the importance of collaboration and information sharing in delivering innovative therapies to patients. Both organizations are committed to improving healthcare globally by leveraging their respective capabilities and pipelines.
In summary, the collaboration between C-Path’s TRxA and Celdara Medical establishes a framework for sharing information and resources in the development of promising new therapeutics. By combining their expertise and pipelines, these organizations aim to accelerate the delivery of innovative treatments to patients with unmet medical needs.
